Nuvation Bio, Inc. (NUVB)
8.31
-0.06
(-0.72%)
USD |
NYSE |
Dec 04, 16:00
8.33
+0.02
(+0.24%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.849B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 202.2% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 105.53 |
| Price to Book Value | 8.742 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6387 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 93.39% |
Profile
| Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY. |
| URL | http://www.nuvationbio.com |
| Investor Relations URL | https://investors.nuvationbio.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Nov. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY. |
| URL | http://www.nuvationbio.com |
| Investor Relations URL | https://investors.nuvationbio.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Nov. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |